Day 1

Introductory remarks

Mike Allen, Regional Medical Advisor (Antibiotics), MSD UK & BSAC General Secretary

Session 1 – Keynote presentation

  • Global Challenges and Goals for AMR – Reflections from the UNGA High Level Meeting

Session 2 – Drug discovery: new targets and new chemistry

Chair: Alan Hennessy, Discovery and Exploratory Research Team Leader, GARDP

  • Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria
    • Douglas Huseby, Uppsala University
  • The Ersilia Model Hub: Open Source AI for Antimicrobial Drug Discovery
    • Miquel Duran-Frigola, Ersilia Open Source Initiative
  • Immunotherapy focused on infectious diseases
    • Pamela Brown, Centauri Therapeutics Ltd

Session 3 – Preclinical antimicrobial development

Chair: François Franceschi, Head of Asset Evaluation and Development and Serious Bacterial Infections Project Leader, GARDP

  • FabI inhibitor for Neisseria gonorrhoeae (Debio1453)
    • David Cameron, Debiopharm
  • EBL-1463, a non-beta-lactam PBP inhibitor impervious to beta-lactamase hydrolysis for the treatment of CRE infections
    • François Moreau, Tamrisa Innovation
  • An Immune Approach for the Treatment of Sepsis
    • Jessica Field, Cellics Therapeutics

Session 4 – Panel discussion 

Chair: Susana Frasés Carvajal, Federal University of Rio de Janeiro

  • The antifungal development pipeline
    • Maurizio Del Poeta, Stony Brook University
    • Leah Cowen, University of Toronto

Day one closing remarks

Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer

Day 2

Introductory remarks

Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer

Session 5 – Clinical Development and Use of New agents
Please note, the recording for Session 5 is currently not available.

Chair: Mike Allen, Regional Medical Advisor (Antibiotics), MSD UK & BSAC General Secretary

  • Development pathways in antibiotic development – This presentation has been developed by Pfizer Inc
    • Halley Rogers, Pfizer Inc
  • The challenges and opportunities in the preclinical development of cefepime-enmetazobactam
    • Maneesh Paul, Microvioma
  • The challenges and opportunities of the development pathway for Phage therapy
    • Ariel Cohen, BiomX/Adaptive Phage Therapeutics

Session 6 – Oral Poster Presentations

Chair: Tom Ashfield, Health Strategist & BSAC Council

  • Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria
    • Sohinee Sarkar, Murdoch Children’s Research Institute
  • Utilising actinobacteria diversity in the Great Salt Plains to look for novel TB therapeutics
    • Amanda Jones, Northumbria University
  • Building an on-panel enzyme detection system to reveal and resolve clinically problematic beta-lactamases in Gram negative bacteria
    • Nicole Jackson, BioAmp Diagnostics
  • Functional high-throughput screening identifies microRNAs regulating infection by Staphylococcus aureus
    • Caio Haddad Franco, AccelBio Collaborative Laboratory, University of Coimbra
  • Computational study to identify novel Metallo-β-lactamases inhibitors using virtual screening, molecular docking, dynamic simulations, and ADMET prediction
    • Fatima Mourabiti, University of Casablanca

Session 7 – Control of infectious diseases with biotherapeutics and beyond

Chair: Fausto Almeida, University of São Paulo

  • The role of vaccines to tackle AMR
    • Angela Brueggemann, University of Oxford
  • Therapeutic antibodies and infectious diseases
    • Liise-anne Pirofski, Albert Einstein College of Medicine and Montefiore Medical Center
  • Jumbo Bacteriophages for IPC
    • Gregorio Iraola, Kinzbio

Session 8 – Panel discussion: Acceleration of development/access of POCTs for STI management

Chair: Teri Roberts, Public Health Senior Manager, GARDP

  • Moving from syndromic to aetiological approaches for STI management: a focus on implementation challenges and opportunities in LMIC settings
    • Chido Dziva Chikwari, London School of Hygiene & Tropical Medicine
  • Developing a low cost N. gonorrhoeae lateral flow assay: challenges and opportunities
    • Cecilia Ferreyra, FINDcec
  • Developer’s experience of developing a test for N. gonorrhoeae and guidance for POCT developers on ceftriaxone-resistant N. gonorrhoeae targets
    • Alex Trick, Prompt Diagnostics
  • Clinical use and uptake of STI POCTs in LMICs
    • Yukari Manabe, Johns Hopkins Center for Innovative Diagnostics for Infectious Diseases
  • Panel discussion and Q&A

Closing remarks

Alison Luckey, GARDP